Background: Laboplatin, D-19466, 1,2-diaminomethylcyclobutaneplatinum(II) lactate, is a novel, water-soluble platinum complex which showed a better therapeutic index than Cisplatin or Carboplatin in murine and human tumor models. In a preceding Phase I study myelosuppression with predominant thrombocytopenia was the dose-limiting toxicity. Besides nausea and vomiting no further side effects were observed. Patients and Methods: The phase II study group of the AIO performed a phase II study in pretreated patients with advanced small-cell lung cancer (SCLC). 19 patients received Lobaplatin without hydration from which 18 were evaluable for toxicity and 17 for antitumor activity. The dose of 40 mg/m2 was given by intravenous bolus injection repeated every 4 weeks. Results: No objective complete or partial remissions were observed. 2 Patients showed a short-lasting no change. Thrombocytopenia was the dose-limiting toxicity: 11/18 (61%) patients presented WHO grades 1-4 and 5 WHO grades 3-4 (28%). The nadir occurred after 2 weeks with recovery within a week. Anemia WHO grades 1-3 were seen in 11 patients (61%), leukopenia grades 1-3 in 10 patients (56%). The nadir of leukopenia occurred after 3 weeks. Nausea and vomiting occurred in two thirds of the patients; however, were well controlled by antiemetics. No renal, CNS or ototoxi-city was observed. Conclusions: In patients heavily pretreated with chemotherapy, Lobaplatin did not show therapeutic activity at the dose of 40 mg/m2, although 33% of the patients experienced a grade 3 or 4 thrombocytopenia as the dose-limiting toxicity. Secondary resistance to chemotherapy and compromised bone marrow reserve due to intensive prior treatment may have contributed to this study outcome since Lobaplatin was clearly active in SCLC patients with no or one prior chemotherapy only, allowing administration of Lobaplatin at a dose of 50 mg/m2 and a repeat interval of 3 weeks.

This content is only available via PDF.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.